Stocktoria
Xenon Pharmaceuticals Inc. XENE
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-10-17
Xenon Pharmaceuticals Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $7.5M | $0 | $0 | $9.4M | $18.4M |
| R&D expense | $300.9M | $210.4M | $167.5M | $105.8M | $75.5M |
| Operating income | -$373.1M | -$279.3M | -$214.1M | -$129.1M | -$79.0M |
| Income tax | $1.0M | -$4.1M | -$292,000 | $118,000 | -$6,000 |
| Net income | -$345.9M | -$234.3M | -$182.4M | -$125.4M | -$78.9M |
| EPS (diluted) | $-4.36 | $-3.01 | $-2.73 | $-2.06 | $-1.77 |
| Operating cash flow | -$279.1M | -$181.4M | -$151.1M | -$101.0M | -$69.5M |
| Free cash flow | -$279.9M | -$184.5M | -$156.7M | -$103.9M | -$71.6M |
| Cash & equivalents | $199.2M | $142.7M | $148.6M | $57.2M | $175.7M |
| Total assets | $633.2M | $798.1M | $964.8M | $754.1M | $572.0M |
| Total liabilities | $51.4M | $43.2M | $36.9M | $32.6M | $22.0M |
| Shareholders' equity | $581.8M | $754.9M | $927.9M | $721.5M | $550.0M |
Source: SEC EDGAR filings · CIK 0001582313 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.